
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a biotech company with a promising outlook, as their proprietary synthetic psilocybin formulation, COMP360, has Breakthrough Therapy designation from the US FDA and has received Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression (TRD). With positive results from phase 2 and 3 clinical trials for TRD and ongoing trials for other mental health disorders, Compass Pathways is well-positioned to become a leader in the emerging field of psychedelic therapies. The company has a strong research bench and a global network of treatment centers, indicating potential for significant future growth.
Bears say
Compass Pathways is facing numerous risks, including clinical, regulatory, and commercial risks, as well as the possibility of dilutive equity offering. Even though their current valuation is approximately $9.6 billion with a price target of $70, there are significant risks to achieving this target, such as clinical development risk, competitor risk, and government regulatory risk. The recent news of a suspected completed suicide in one of their trials also brings up concerns about the safety and efficacy of their treatment. Overall, there are significant uncertainties surrounding Compass Pathways, making it a risky investment.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares